Cognito Therapeutics Raises $73 Million, Plans To Advance Its Neurotechnology Platform For Alzheimer’s Disease

Cognito Therapeutics, a neurotechnology company focused on central nervous system diseases, raised $73 million in investment funding which it plans to use to continue developing its neurotechnology platform focused on Alzheimer’s disease. The company is developing a non-invasive neuromodulation device, which delivers proprietary gamma frequency light and sound stimulation intended to treat Alzheimer’s disease.

In a prior Phase 2 clinical trial, Cognito’s device demonstrated a significant slowing in functional and cognitive decline in the treatment group, as well as a significant decline in brain atrophy over a six-month period. To further demonstrate the efficacy of . . .